for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bausch Health Companies Inc

BHC.TO

Latest Trade

37.30CAD

Change

-1.03(-2.69%)

Volume

488,669

Today's Range

37.00

 - 

38.50

52 Week Range

24.89

 - 

42.15

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bausch + Lomb - Announced U.S. Launch Of Expanded Parameters For Biotrue Oneday For Astigmatism Daily Disposable Contact Lenses

Jan 6 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH + LOMB - ANNOUNCED U.S. LAUNCH OF EXPANDED PARAMETERS FOR BIOTRUE ONEDAY FOR ASTIGMATISM DAILY DISPOSABLE CONTACT LENSES.

Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction

Dec 20 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH LICENSES NOVALIQ'S NOV03 INVESTIGATIONAL TREATMENT FOR DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION.BAUSCH HEALTH COMPANIES INC - NOVALIQ IS ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS.BAUSCH HEALTH COMPANIES INC - A PHASE 3 STUDY IS UNDERWAY FOR NOV03, AND CO ANTICIPATES STARTING AN ADDITIONAL PHASE 3 STUDY IN 2020.BAUSCH HEALTH COMPANIES INC - ACQUIRED EXCLUSIVE LICENSE FOR COMMERCIALIZATION AND DEVELOPMENT IN U.S. & CANADA OF INVESTIGATIONAL TREATMENT NOV03.BAUSCH HEALTH COMPANIES INC - NOVALIQ IS ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES.BAUSCH HEALTH - HAS RIGHT TO PURSUE DEVELOPMENT & COMMERCIALIZATION OF NOV03 FOR DED AND COMBINATION PRODUCTS IN U.S. & CANADA.BAUSCH HEALTH - NOVALIQ WILL BE ELIGIBLE TO RECEIVE ADDITIONAL UNDISCLOSED MILESTONE PAYMENTS PLUS ROYALTIES FOR ANY RESULTING COMBINATION PRODUCTS.

Bausch Health Announces Resolution Of BRYHALI Lotion Intellectual Property Litigation With Glenmark

Dec 20 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH ANNOUNCES RESOLUTION OF BRYHALI® (HALOBETASOL PROPIONATE) LOTION, 0.01%, INTELLECTUAL PROPERTY LITIGATION WITH GLENMARK.BAUSCH HEALTH COMPANIES INC - ORTHO DERMATOLOGICS WILL MAINTAIN MARKET EXCLUSIVITY FOR BRYHALI LOTION UNTIL 2026.BAUSCH HEALTH COMPANIES - WILL GRANT GLENMARK A NON-EXCLUSIVE LICENSE EFFECTIVE 2026 TO ITS INTELLECTUAL PROPERTY RELATING TO BRYHALI LOTION IN U.S..BAUSCH HEALTH COMPANIES - CO & UNIT AGREED TO RESOLVE INTELLECTUAL PROPERTY LITIGATION WITH GLENMARK PHARMACEUTICALS REGARDING BRYHALI LOTION, 0.01%.BAUSCH HEALTH COMPANIES INC - FINAL PATENT EXPIRY ON BRYHALI LOTION IS 2031.

FDA Approves Ortho Dermatologics' Arazlotm (Tazarotene) Lotion, 0.045%, For Acne Vulgaris

Dec 19 (Reuters) - Bausch Health Companies Inc <BHC.TO>::FDA APPROVES ORTHO DERMATOLOGICS' ARAZLOTM (TAZAROTENE) LOTION, 0.045%, FOR ACNE VULGARIS.

Bausch Health Announces Conditional Redemption Of Existing Senior Notes

Dec 18 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH ANNOUNCES CONDITIONAL REDEMPTION OF EXISTING SENIOR NOTES.BAUSCH HEALTH - ISSUED CONDITIONAL NOTICE OF REDEMPTION FOR $1.240 BILLION AGGREGATE PRINCIPAL AMOUNT OF CO'S OUTSTANDING 5.875% SENIOR NOTES DUE 2023.BAUSCH HEALTH - REDEMPTION OF 2023 NOTES CONDITIONED ON CLOSING OF OFFERING OF DEBT SECURITIES BY CO GENERATING GROSS PROCEEDS OF AT LEAST $2.5 BILLION.

Bausch Health Announces Pricing Of Private Offering Of Senior Notes

Dec 17 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR NOTES.BAUSCH HEALTH COMPANIES INC - PRICED OFFERING OF $1.25 BILLION 5.000% SENIOR NOTES DUE 2028 AND $1.25 BILLION 5.250% SENIOR NOTES DUE 2030.BAUSCH HEALTH COMPANIES INC - AGGREGATE SIZE OF OFFERING OF NOTES IS $2.5 BILLION, WHICH REFLECTS INCREASE OF $1.25 BILLION.BAUSCH HEALTH COMPANIES INC - 2028 NOTES WILL BE SOLD TO INVESTORS AT A PRICE OF 100% OF PRINCIPAL AMOUNT THEREOF.BAUSCH HEALTH COMPANIES INC - 2030 NOTES WILL BE SOLD TO INVESTORS AT A PRICE OF 100% OF PRINCIPAL AMOUNT THEREOF.

Bausch Health Announces Launch Of Private Offering Of Senior Notes

Dec 17 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES.BAUSCH HEALTH COMPANIES - LAUNCHED AN OFFERING OF A COMBINED $1.25 BILLION OF NEW SENIOR NOTES DUE 2028 AND NEW SENIOR NOTES DUE 2030.BAUSCH HEALTH - INTENDS TO USE OFFERING PROCEEDS TO FINANCE CO'S SETTLEMENT AGREEMENT RELATING TO U.S. PUTATIVE SECURITIES CLASS LITIGATION.

Bausch Health Resolves "Stock Drop" Litigation Initially Filed In October 2015

Dec 16 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH RESOLVES "STOCK DROP" LITIGATION INITIALLY FILED IN OCTOBER 2015.BAUSCH HEALTH - PARTIES IN SECURITIES CLASS ACTION VALEANT PHARMACEUTICALS INTERNATIONAL, FILED IN U.S. DISTRICT COURT AGREED TO RESOLVE ACTION FOR $1.21 BILLION.BAUSCH HEALTH COMPANIES INC - AGREED SETTLEMENT TIMING INCLUDES A PAYMENT SCHEDULE WITH FIRST FUNDING IN MID-JANUARY 2020.BAUSCH HEALTH COMPANIES INC - SETTLEMENT DOES NOT IMPACT COMPANY'S CURRENT 2019 FINANCIAL GUIDANCE.BAUSCH HEALTH - TO USE CASH ON HAND, ITS REVOLVING CREDIT FACILITY, POTENTIALLY ACCESSING CAPITAL MARKETS TO FUND SETTLEMENT.

Bausch Health Companies Posts Q3 Loss Per Share $0.14

Nov 4 (Reuters) - Bausch Health Companies Inc <BHC.TO>::. ANNOUNCES THIRD-QUARTER 2019 RESULTS AND RAISES FULL-YEAR REVENUE AND ADJUSTED EBITDA (NON-GAAP) GUIDANCE RANGES.QTRLY REVENUES OF $2.209 BILLION.Q3 LOSS PER SHARE $0.14.SEES FY 2019 REVENUE $8.475 BILLION TO C$8.625 BILLION.BAUSCH HEALTH'S CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $827 MILLION AT SEPT. 30, 2019.RAISED FULL-YEAR ADJUSTED EBITDA RANGE FROM $3.425 - $3.575 BILLION TO $3.50 - $3.60 BILLION.RAISED FULL-YEAR REVENUE RANGE FROM $8.40 - $8.60 BILLION TO $8.475 - $8.625 BILLION.

Bausch Health Licenses Clearside Biomedical's Xipere, An Investigational Treatment For Macular Edema Associated With Uveitis

Oct 23 (Reuters) - Bausch Health Companies Inc <BHC.TO>::BAUSCH HEALTH LICENSES CLEARSIDE BIOMEDICAL'S XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION), AN INVESTIGATIONAL TREATMENT FOR MACULAR EDEMA ASSOCIATED WITH UVEITIS.BAUSCH HEALTH COMPANIES INC - CLEARSIDE EXPECTS TO RESUBMIT ITS NDA FOR XIPERE TO FDA FOR REVIEW IN Q1 OF 2020.BAUSCH HEALTH COMPANIES INC - UNDER TERMS OF AGREEMENT, CLEARSIDE WILL RECEIVE UP TO $20 MILLION IN PAYMENTS PRIOR TO LAUNCH.BAUSCH HEALTH COMPANIES INC - CLEARSIDE ALSO ENTITLED TO RECEIVE TIERED ROYALTIES BASED ON ANNUAL NET SALES OF XIPERE IN UNITED STATES AND CANADA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up